| Filed On | Filing |
|---|---|
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
In-licensing of ex-China rights to two potentially best-in-class compounds (NXP100 and NXP200) from Haisco Pharmaceutical Group transformed Nuvectis into a late-stage clinical development company. |
| 21 Aug 2026 |
8-K: Other Events
Nuvectis Pharma, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares ... |
| 04 Aug 2026 |
8-K: Results of Operations and Financial Condition
Completed in-licensing of ex-China rights to two potentially best-in-class compounds (NXP100 and NXP200) from Haisco Pharmaceutical Group (“Haisco”), transforming the company into a late-stage clinical development organization. |
| 30 Jun 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
As Representative of the several Underwriters listed on Schedule IA hereto |
| 29 Jun 2026 |
8-K: Other Events
As previously disclosed, on May 9, 2025, Nuvectis Pharma, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Leerink Partners LLC (the “Agent”) pursuant to which the Company may sell, from time to time, at i... |
| 23 Jun 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds |
| 12 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On Thursday, June 11, 2026, at 10:00 a.m. Eastern Time, by means of an online meeting platform, Nuvectis Pharma, Inc. (the “Company”) held its 2026 Annual Meeting (the “Annual Meeting”). |
| 05 May 2026 |
8-K: Results of Operations and Financial Condition
NXP900 Phase 1b clinical program continues to enroll patients at select sites in the US |
| 11 Feb 2026 |
8-K: Results of Operations and Financial Condition
Fort Lee, NJ, February 11, 2026 (GLOBE NEWSWIRE) - Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatm... |
| 04 Nov 2025 |
8-K: Results of Operations and Financial Condition
NXP900 Phase 1b program initiated; single agent study underway, aiming to provide preliminary evidence of clinical efficacy in patients with molecularly and histologically defined advanced cancers; initiation of the combination portion o... |
| 25 Sep 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Fort Lee, NJ – September 25, 2025 –– Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical n... |
| 05 Aug 2025 |
8-K: Results of Operations and Financial Condition
NXP900 becomes the lead drug candidate after successfully completing the Phase 1a dose escalation study in patients with advanced solid tumors and a drug-drug interaction study in healthy volunteers; initiation of Phase 1b program is imm... |
| 13 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On Thursday, June 12, 2025, at 10:00 a.m. Eastern Time, by means of an online meeting platform, Nuvectis Pharma, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). Stockholders representing 14,605,1... |
| 09 May 2025 |
8-K: Other Events
Nuvectis Pharma, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows: |
| 06 May 2025 |
8-K: Results of Operations and Financial Condition
NXP900 clinical data presentation from the Phase 1a dose escalation study at the 2025 AACR conference demonstrated robust pharmacodynamic response and acceptable safety at clinically relevant doses; preclinical data presentations further... |
| 25 Feb 2025 |
8-K: Results of Operations and Financial Condition
NXP800 Phase 1b study in patients with platinum resistant, ARID1a-mutated ovarian cancer is ongoing; Orphan Drug Designation granted by the U.S. FDA. Updated Phase 1b results anticipated in Q2 2025 |
| 06 Feb 2025 |
8-K: Entry into a Material Definitive Agreement; Other Events
Nuvectis Pharma, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to Lucid Capital Markets, LLC (the “Underwriter”) an aggregate of 2,700,000 authorized but unis... |
| 05 Nov 2024 |
8-K: Results of Operations and Financial Condition
Clinical data update from the NXP800 Phase 1b study expected this month; NXP800 granted Orphan Drug Designation for the treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers |
| 29 Aug 2024 |
8-K: Other Events
Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers |
| 06 Aug 2024 |
8-K: Results of Operations and Financial Condition
August 6, 2024, Fort Lee, NJ - Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious condi... |
Loading...